Roche Launches Cobas B 123 Mobile Blood Gas Analyzer

Roche Launches Cobas B 123 Mobile Blood Gas Analyzer in U.S.

Roche has announced the release of the Cobas B 123 Point-of-care (POC) blood gas analyzer in the United States. The system delivers the regular blood gas parameters together with electrolytes, glucose and lactate within 2 minutes. One of the problems in point of care blood analyzers is clot formation. A special protection system helps prevent downtime due to clots from the reagent fluid packs. The only manual maintenance steps required are the replacement of consumables, making it ideal for use in POC settings.

The system can analyze pO2, pCO2, pH, Hct, Na+, K+, Ca++, Cl–, glucose, lactate, tHb, SO2, O2Hb, HHb, COHb, MetHb, neonatal bilirubin and calculate more than 30 other clinically useful parameters. Results can be automatically printed or transmitted to the laboratory information system.

The sample input area remains closed during operation between samples and there are no exposed needles in the system. Waste is collected in a sealed pack within the closed system and can be removed easily. The device is easy to handle and can be moved on a cart which makes it ideal for use throughout the hospital, especially when linked to the Cobas IT 1000 application. With the IT solutions package you can manage the cobas POC analyzers from your desk. The IT system offers remote configuration and control of all connected POC devices including all the warnings, alerts and measurement results.

Joe Crowley, senior vice president, Professional Diagnostics-Hospital, at Roche Diagnostics Corporation:

“The addition of the cobas b 123 POC system to our blood gas analyzer portfolio enables hospitals to provide lab-like accuracy for blood gas testing at the point of care, while reducing their potential maintenance requirements. As a result, respiratory therapists and other caregivers can spend more of their time focusing on patients and their needs.”

Roche introduces mobile blood gas analyzer for hospital point of care

System offers next-generation technology to virtually eliminate downtime due to blood clots

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the U.S. introduction of the cobas b 123 POC system, a mobile blood gas analyzer designed for hospital point-of-care settings. The system¡¦s next-generation technology helps ensure reliable performance by virtually eliminating the introduction of blood clots that can contribute to analyzer downtime and negatively impact patient care.

¡§The addition of the cobas b 123 POC system to our blood gas analyzer portfolio enables hospitals to provide lab-like accuracy for blood gas testing at the point of care, while reducing their potential maintenance requirements ,¡¨ said Joe Crowley, senior vice president, Professional Diagnostics-Hospital, at Roche Diagnostics Corporation. ¡§As a result, respiratory therapists and other caregivers can spend more of their time focusing on patients and their needs.¡¨

With patented thick-film sensor technology and a broad assay menu that includes lactate, the cobas b 123 POC system offers fast turnaround time for 15 important critical-care blood gas and electrolyte tests. It has a mobile cart to facilitate use in a variety of areas, from the intensive care unit to the patient floor. In addition, the cobas b 123 POC system offers automated linearity testing and calibration to simplify both workflow and regulatory compliance.

The analyzer features an unparalleled four-level clot protection system that helps prevent downtime caused by the introduction of clots that lead to fluid pack failures¡Xa major issue for healthcare facilities because replacing the pack takes time away from patient care and wastes usable reagent. In addition, the fluid packs for the cobas b 123 POC system require no refrigeration and include smart chips, allowing them to be easily transferred between similar devices and helping hospitals control

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world¡¦s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche¡¦s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.

All trademarks used or mentioned in this release are protected by law.

For further information, please contact:

Jennifer Zinn Vice President, Commercial Education and Communications

Roche Diagnostics Corporation

Indianapolis, IN (317) 521-4245 jennifer.zinn@roche.com

The product specific internet site that you have requested is intended for non-U.S. residents. As a result, the site may contain information on diagnostics, medical devices and other products or uses of those products that are not approved in certain countries or regions. If you are a resident of a country other than those to which the site is directed, please return to roche.com or contact your local Roche Representative to obtain the appropriate product information for your country of residence.

Source :http://www.roche-diagnostics.us/PressRoom/PressReleases/Roche%20cobas%20b%20123%20Release_final%20TS%20comments.pdf

Related Posts Plugin for WordPress, Blogger...
Be Sociable, Share!

About the Author

has written 1822 posts on this blog.

Copyright © 2017 Medical Technology & Gadgets Blog MedicalBuy.net. All rights reserved.
Proudly powered by WordPress. Developed by Deluxe Themes